Your browser doesn't support javascript.
loading
Enrichment of SARM1 alleles encoding variants with constitutively hyperactive NADase in patients with ALS and other motor nerve disorders.
Gilley, Jonathan; Jackson, Oscar; Pipis, Menelaos; Estiar, Mehrdad A; Al-Chalabi, Ammar; Danzi, Matt C; van Eijk, Kristel R; Goutman, Stephen A; Harms, Matthew B; Houlden, Henry; Iacoangeli, Alfredo; Kaye, Julia; Lima, Leandro; Ravits, John; Rouleau, Guy A; Schüle, Rebecca; Xu, Jishu; Züchner, Stephan; Cooper-Knock, Johnathan; Gan-Or, Ziv; Reilly, Mary M; Coleman, Michael P.
Affiliation
  • Gilley J; John van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom.
  • Jackson O; John van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom.
  • Pipis M; Department of Neuromuscular Disease, UCL Queen Square Institute of Neurology and The National Hospital for Neurology, London, United Kingdom.
  • Estiar MA; Department of Human Genetics, McGill University, Montreal, Canada.
  • Al-Chalabi A; The Neuro (Montreal Neurological Institute-Hospital), McGill University, Montreal, Canada.
  • Danzi MC; Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.
  • van Eijk KR; Department of Neurology, King's College Hospital, King's College London, London, United Kingdom.
  • Goutman SA; Dr. John T. Macdonald Foundation Department of Human Genetics and John P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, United States.
  • Harms MB; Department of Neurology, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands.
  • Houlden H; Department of Neurology, University of Michigan, Ann Arbor, United States.
  • Iacoangeli A; Institute for Genomic Medicine, Columbia University, New York, United States.
  • Kaye J; Department of Neuromuscular Disease, UCL Queen Square Institute of Neurology and The National Hospital for Neurology, London, United Kingdom.
  • Lima L; Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.
  • Ravits J; National Institute for Health Research Biomedical Research Centre and Dementia Unit at South London and Maudsley NHS Foundation Trust and King's College London, London, United Kingdom.
  • Rouleau GA; Center for Systems and Therapeutics, Gladstone Institutes, San Francisco, United States.
  • Schüle R; Center for Systems and Therapeutics, Gladstone Institutes, San Francisco, United States.
  • Xu J; Gladstone Institute of Data Science and Biotechnology, Gladstone Institutes, San Francisco, United States.
  • Züchner S; Department of Neuromuscular Disease, UCL Queen Square Institute of Neurology and The National Hospital for Neurology, London, United Kingdom.
  • Cooper-Knock J; Department of Neurosciences, University of California, San Diego, La Jolla, United States.
  • Gan-Or Z; Department of Human Genetics, McGill University, Montreal, Canada.
  • Reilly MM; The Neuro (Montreal Neurological Institute-Hospital), McGill University, Montreal, Canada.
  • Coleman MP; Department of Neurology and Neurosurgery, McGill University, Montreal, Canada.
Elife ; 102021 11 19.
Article in En | MEDLINE | ID: mdl-34796871
ABSTRACT
SARM1, a protein with critical NADase activity, is a central executioner in a conserved programme of axon degeneration. We report seven rare missense or in-frame microdeletion human SARM1 variant alleles in patients with amyotrophic lateral sclerosis (ALS) or other motor nerve disorders that alter the SARM1 auto-inhibitory ARM domain and constitutively hyperactivate SARM1 NADase activity. The constitutive NADase activity of these seven variants is similar to that of SARM1 lacking the entire ARM domain and greatly exceeds the activity of wild-type SARM1, even in the presence of nicotinamide mononucleotide (NMN), its physiological activator. This rise in constitutive activity alone is enough to promote neuronal degeneration in response to otherwise non-harmful, mild stress. Importantly, these strong gain-of-function alleles are completely patient-specific in the cohorts studied and show a highly significant association with disease at the single gene level. These findings of disease-associated coding variants that alter SARM1 function build on previously reported genome-wide significant association with ALS for a neighbouring, more common SARM1 intragenic single nucleotide polymorphism (SNP) to support a contributory role of SARM1 in these disorders. A broad phenotypic heterogeneity and variable age-of-onset of disease among patients with these alleles also raises intriguing questions about the pathogenic mechanism of hyperactive SARM1 variants.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: NAD/ Nucleosidase / Amyotrophic Lateral Sclerosis Limits: Adult / Aged / Animals / Female / Humans / Male / Middle aged Language: En Journal: Elife Year: 2021 Type: Article Affiliation country: United kingdom

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: NAD/ Nucleosidase / Amyotrophic Lateral Sclerosis Limits: Adult / Aged / Animals / Female / Humans / Male / Middle aged Language: En Journal: Elife Year: 2021 Type: Article Affiliation country: United kingdom